OA16419A - Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking. - Google Patents
Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking. Download PDFInfo
- Publication number
- OA16419A OA16419A OA1201400062 OA16419A OA 16419 A OA16419 A OA 16419A OA 1201400062 OA1201400062 OA 1201400062 OA 16419 A OA16419 A OA 16419A
- Authority
- OA
- OAPI
- Prior art keywords
- hemoglobin
- crosslinked
- beta
- heat stable
- red blood
- Prior art date
Links
- 239000001301 oxygen Substances 0.000 title claims abstract description 102
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 102
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 title claims abstract description 101
- 238000004132 cross linking Methods 0.000 title claims abstract description 64
- 239000000969 carrier Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 19
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 257
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 257
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 239000012535 impurity Substances 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- 210000002381 Plasma Anatomy 0.000 claims abstract description 25
- 101700014779 GLB1 Proteins 0.000 claims abstract description 6
- 210000003743 Erythrocytes Anatomy 0.000 claims description 70
- 210000003324 RBC Anatomy 0.000 claims description 70
- 235000018102 proteins Nutrition 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 210000004369 Blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- 241000283690 Bos taurus Species 0.000 claims description 30
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims description 27
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 27
- 238000001816 cooling Methods 0.000 claims description 19
- 239000000539 dimer Substances 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 19
- 239000006166 lysate Substances 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 16
- 210000001519 tissues Anatomy 0.000 claims description 14
- 238000004806 packaging method and process Methods 0.000 claims description 11
- 239000002699 waste material Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000012465 retentate Substances 0.000 claims description 10
- 230000035699 permeability Effects 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- 230000001706 oxygenating Effects 0.000 claims 4
- 238000005341 cation exchange Methods 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 206010047139 Vasoconstriction Diseases 0.000 abstract description 3
- 230000025033 vasoconstriction Effects 0.000 abstract description 3
- 206010061481 Renal injury Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 238000006213 oxygenation reaction Methods 0.000 abstract 1
- 230000000287 tissue oxygenation Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 40
- 230000009089 cytolysis Effects 0.000 description 28
- 238000000108 ultra-filtration Methods 0.000 description 19
- 230000002934 lysing Effects 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 108010061951 Methemoglobin Proteins 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 208000001953 Hypotension Diseases 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 206010057248 Cell death Diseases 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000005755 formation reaction Methods 0.000 description 11
- 102100001249 ALB Human genes 0.000 description 10
- 101710027066 ALB Proteins 0.000 description 10
- 102000003846 Carbonic Anhydrases Human genes 0.000 description 10
- 108090000209 Carbonic Anhydrases Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 229940050528 albumin Drugs 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 230000035939 shock Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 102000018146 globin family Human genes 0.000 description 8
- 108060003196 globin family Proteins 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 210000000265 Leukocytes Anatomy 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 206010022114 Injury Diseases 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 229940067631 Phospholipids Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000710188 Encephalomyocarditis virus Species 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 5
- 230000003068 static Effects 0.000 description 5
- 229960001322 trypsin Drugs 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 241000701922 Bovine parvovirus Species 0.000 description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 4
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 239000004698 Polyethylene (PE) Substances 0.000 description 4
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 4
- 238000005040 ion trap Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000009517 secondary packaging Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 102100019126 HBB Human genes 0.000 description 2
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 2
- RKCAIXNGYQCCAL-UHFFFAOYSA-N Porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000011052 biological reactivity test Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007705 chemical test Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001186 cumulative Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000001627 detrimental Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000003278 haem Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002648 laminated material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- 235000019263 trisodium citrate Nutrition 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 230000037227 Blood Loss Effects 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000725581 Frog erythrocytic virus Species 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N Iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 102100019096 MB Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 229940056345 Tums Drugs 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 238000004850 capillary HPLC Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007623 carbamidomethylation reaction Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000034327 globular proteins Human genes 0.000 description 1
- 108091005889 globular proteins Proteins 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 101700025122 nac-1 Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 108010001708 stroma free hemoglobin Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-Cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Abstract
Methods for preparation of a heat stable hemoglobin based oxygen-carrier-containing pharmaceutical composition such that beta-beta cross-linking is favored are provided. Using the methods of the present invention, the oxygen affinity of the resultant molecule can be controlled so that hemoglobin based oxygen carriers tailored for specific applications can be produced. Lower oxygen affinity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygenation (e.g. hemorrhagic shock) while higher oxygen affinity cross-linked hemoglobin is useful for applications requiring a slower rate of oxygenation (e.g. cancer adjunct therapy). A highly purified and heat stable crosslinked non-polymeric tetrameric hemoglobin having beta- beta crosslinking of greater than 40-60% and suitable for use in mammals without causing renal injury and vasoconstriction is produced. A high temperature and short time (HTST) heat processing step is performed to effectively remove any undesired dimeric hemoglobin, non- crosslinked tetrameric hemoglobin, and plasma protein impurities.
Description
[001] The présent invention relates to methods for the préparation of a heat stable oxygen-carrier-containing pharmaceutical composition such that beta-beta cross-linking is favored. Using the methods of the présent invention, the oxygen affinity of the resulting 25 molécule can be controlled so that hemoglobin based oxygen carriers tailored for spécifie applications can be produced. Lower oxygen affinity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygénation (e.g. hémorrhagie shock) while higher oxygen affinity crosslinked hemoglobin is useful for applications requiring a slower rate of oxygénation (e.g. cancer adjunct therapy).
Background of Invention [002] Hemoglobin plays an important rôle in most vertebrates for gaseous exchange between the vascular System and tissue. It is responsible for carryîng oxygen from the respiratory System to the body cells via blood circulation and also carrying the metabolic waste product carbon dioxide away from body cells to the respiratory System, where the carbon dioxide is exhaled. Since hemoglobin has this oxygen transport feature, it can be used as a potent oxygen supplier if it can be stabilized ex vivo and used in vivo.
[003] Naturally-occurring hemoglobin is a tetramer which is generally stable when présent within red blood cells. However, when naturally-occurring hemoglobin is removed from red blood cells, it becomes unstable in plasma and splits into two α-β dimers. Each of these dimers is approximately 32 kDa in molecular weight. These dimers may cause substantial rénal injury when filtered through the kidneys and excreted. The breakdown of the tetramer linkage also negatively impacts the sustainability of the functional hemoglobin in circulation.
[004] In order to solve the problem, recent developments in hemoglobin processing hâve incorporated various cross-linking techniques to create intramolecular bonds within the tetramer as well as intermolecular bonds between the tetramers to form polymeric hemoglobin. The prior art teaches that polymeric hemoglobin is the preferred form in order to increase circulatory half-life of the hemoglobin. However, as determined by the présent inventors, polymeric hemoglobin more readily converts to met-hemoglobin in blood circulation. Met-hemoglobin cannot bind oxygen and therefore cannot oxygenate tissue, Therefore, the cross-linking taught by the prior art that causes the formation of polymeric hemoglobin is a problem. There is a need in the art for a technique that permits intramolecular cross-linking to create stable tetramers without the simultaneous formation of polymeric hemoglobin.
[005] Further problems with the prior art attempts to stabilize hemoglobin include production of tetrameric hemoglobin that includes an unacceptably high percentage of dimer units (or non-crosslinked tetrameric hemoglobin that quickly dissociâtes to dimeric hemoglobin if administered to a patient); the presence of dimers makes the hemoglobin composition unsatisfactory for administration to mammals. The dimeric form of the hemoglobin can cause severe rénal injury in a mammalian body; this rénal injury can be severe enough to cause death. Therefore, there is a need in the art to create stable tetrameric hemoglobin with undetectable dimeric form in the final product.
[006] Another problem with prior art hemoglobin products is a sudden increase in blood pressure following administration. In the past, vasoconstriction events hâve been recorded from older génération of hemoglobin based oxygen carriers. Thus there is a need in the art for a process to préparé hemoglobin which will not cause vasoconstriction and high blood pressure when applied to a mammal.
[007] Further problème with prior art attempts to create stable hemoglobin include the presence of protein impurities such as immunoglobin G that can cause allergie effects in mammals. Therefore, there is a need in the art for a process which can produce stable tetrameric hemoglobin without protein impurities.
[008] In addition to the above problems, there is a need in the art for stabilized tetrameric hemoglobin that is dimer free, phospholipid free and capable of production on an industrial scale.
[009] Hemoglobin-based oxygen carriers can be used in a wide variety of medical applications; depending upon the medical application, different levels of oxygen affinity are désirable. For example, a hemoglobin molécule with low oxygen affïnity can transfer oxygen more easily to a target tissue than a hemoglobin molécule with higher oxygen affïnity. Therefore it would be désirable to control the oxygen affïnity of the crosslinked tetrameric hemoglobin. Thus, there is a need in the art to control the type of cross-linking and cross-linking conditions to produce crosslinked tetrameric hemoglobin with précisé levels of oxygen binding.
Summary of Invention [00 ΙΟ] The présent invention provides a method for processing a non-polymeric, heat stable purified crosslinked tetrameric hemoglobin suitable for use in mammals without causing severe rénal injury, vascular detrimental effects and severe adverse events including death. The présent invention removes the dimeric form of hemoglobin, noncrosslinked tetrameric hemoglobin, phospholipids and protein impurities. The présent invention also provides a technique for controlling the oxygen affinity of the résultant crosslinked tetramer by controlling the type of cross-linking in the tetramer (e.g., the amount of beta-beta cross-linking, alpha-alpha cross-linking, alpha-beta cross-linking in the tetramer), the quaternary structure of tetramer, and the cross-linking conditions. Lower oxygen affinity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygénation (e.g. hémorrhagie shock) while higher oxygen affinity crosslinked hemoglobin is useful for applications requiring a slower rate of oxygénation (e.g. cancer adjunct therapy). Additionally, the présent invention uses (l) an instant cytolysis apparatus for précisé and controlled hypotonie lysis, (2) a flowthrough column chromatography, (3) a high température short time (HTST) apparatus for heat processing the hemoglobin solution in the purification process to remove the undesirable non-stabilized dimers of hemoglobin and to remove the protein impurities, for example immunoglobin-G, so that rénal injury, vascular detrimental effects and other toxicity reactions can be avoided, and (4) an air-tight infusion bag packaging to avoid oxygen intrusion into the final product.
[0011] The method includes a starting material of mammalian whole blood including at least red blood cells and plasma. Red blood cells are separated from the plasma in the mammalian whole blood followed by filtering to obtain a filtered red blood cell fraction, The filtered red blood cell fraction is washed to remove plasma protein impurities. The washed red blood cells are dîsrupted by a controlled hypotonie lysis for a time sufficient to lyse red blood cells without lysing white blood cells in an instant cytolysis apparatus. Filtration is performed to remove at least a portion of the waste retentate from the lysate. A first hemoglobin solution is extracted from the lysate. u/~ [0012] One or more purification processes are performed on the hemoglobin solution such as ultrafiltration and/or chromatography.
[0013] The purified hemoglobin is crosslinked by bis-3,5-dibromosalicyl fumarate (DBSF) to form heat stable crosslinked hemoglobin without the formation of polymeric hemoglobin such that the molecular weight of the résultant non-polymeric crosslinked tetrameric hemoglobin is 60-70 kDa. The expression “non-polymeric” as used herein, refers to tetrameric hemoglobin that is not intermolecularly crosslinked with other hemoglobin molécules or any other non-hemoglobin molécules such as PEG. Depending upon the hemoglobin source, the quatemary structure of the hemoglobin and on the crosslinking conditions, a tetrameric product with a high percentage of beta-beta cross-linking can be produced. Further, the oxygen affinity of the résultant molécule can be controlled so that hemoglobin based oxygen carriers tailored for spécifie applications can be produced.
[0014] Following this procedure, the crosslinked hemoglobin is heat-treated to remove any residual non-crosslinked tetrameric hemoglobin and any non-stabilized hemoglobin, for example the dimeric form of hemoglobin, and any other protein impurities. Prior to the heat treatment N-acetyl cysteine is optionally added at a concentration of approximately 0.2% to the crosslinked tetrameric hemoglobin to prevent formation of met-hemoglobin. Immedîately following heat treatment and cooling, N-acetyl cysteine is optionally added at a concentration of approximately 0.025% to 0.4% to further prevent formation of methemoglobin. The heat treatment is preferably a high température short time treatment conducted at approximately 70°C to 95°C for 30 seconds to 3 hours with subséquent cooling to 25°C. Any précipitâtes formed during the heat treatment are removed by centrifugation or filtration.
[0015] The dimer-free, phospholipid-free, protein impurities-free, heat stable, nonpolymeric crosslinked tetrameric hemoglobin is then added to a pharmaceutically acceptable carrier.
[0016] Thereafter, the heat stable, crosslinked tetrameric hemoglobin is formulated and packaged in a custom-made and air-tight polyethylene, ethylene-vinyl-acetate, and ethylene-vînyl alcohol (PE, EVA, EVOH) infusion bag. The packaging prevents oxygen contamination which results in the formation of inactive met-hemoglobin.
Brief Description of the Drawings [0017] FIG. 1 is a flow-chart depicting an overview of a process of the présent invention.
[0018] FIG. 2 schematically depicts an instant cytolysis apparatus used in the process of the présent invention.
[0019] FIG. 3 depicts high performance liquid chromatography analysis for (a) non-heat treated crosslinked tetrameric hemoglobin, and (b) heat stable crosslinked tetrameric hemoglobin which has undergone a heat treatment at 90°C for 45 seconds to 2 minutes or 80°C for 30 minutes.
[0020] FIG. 4 is an elution profde for flowthrough column chromatography; the hemoglobin solution is in the flowthrough fraction.
[0021] FIG. 5 schematically depicts a flowthrough CM column chromatography System with ultrafiltration for an industrial scale operation.
[0022] FIG. 6 is a schematic depiction of an apparatus used for HTST heat processing step [0023] FIG. 7 demonstrates the température profile in the HTST processing apparatus and the time taken to remove unstabilized tetramer (dimer) in the System at 85°C and 90°C of the présent invention.
[0024] FIG. 8 is a schematic depiction of an infusion bag for the heat stable crosslinked tetrameric hemoglobin of the présent invention.
[0025] FIG. 9 depicts reverse phase HPLC chromatogram of a and β globin chains of bovine hemoglobin before (dashed line) and after (solid line) reaction with DBSF under deoxygenated environment.
[0026] FIG. 10 depicts I5% SDS-PAGE analysis of (A) native bovine hemoglobin and (B) hemoglobin crosslinked with DBSF under deoxygenated condition.
[0027] FIG. 11 depicts the peptide mass fingerprint of trypsin-digested peptides from the dimeric protein band (B6) generated by MALDI-TOF analysis.
I0
Dctailed Description of Invention [0028] Hemoglobin is an iron-containing oxygen-transport protein in red blood cells of the blood of mammals and other animais. Hemoglobin exhibits characteristics of both the tertiary and quatemary structures of proteins. Most of the amino acids in hemoglobin form 15 alpha helices connected by short non-helîcal segments. Hydrogen bonds stabilize the helical sections inside the hemoglobin causing attractions within the molécule thereto folding each polypeptide chain into a spécifie shape. A hemoglobin molécule is assembled from four globular protein subunits. Each subunit is composed of a polypeptide chain arranged into a set of α-helix structural segments connected in a “myoglobin fold” 20 arrangement with an embedded heme group.
[0029] The heme group consists of an iron atom held in a heterocyclic ring, known as a porphyrin. The iron atom binds equally to ail four nitrogen atoms in the center of the ring which lie in one plane. Oxygen is then able to bind to the iron center perpendicular to the 25 plane of the porphyrin ring. Thus a single hemoglobin molécule has the capacity to combine with four molécules of oxygen.
[0030] In mammals, the most common type of hemoglobin is a tetramer; in humans, it is called hemoglobin A and consists of two a and two β non-covalently bound subunits 30 designated as α2β2, each made of I4l and 146 amino acid residues respectively. The size and structure of a and β subunits are very similar to each other. Each subunit has a molecular weight of about 16 kDa for a total molecular weight of the tetramer of about 65 kDa. The four polypeptide chains are bound to each other by sait bridges, hydrogen bonds and hydrophobie interaction. The structure of bovine hemoglobin is similar to human hemoglobin (90.14% identity in a chain; 84.35% identity in β chain). The différence is the two sulfhydryl groups in the bovine hemoglobin positioned at β Cys 93, while the sulfhydryls in human hemoglobin are at positioned at a Cys 104, β Cys 93 and β Cys 112 respectively. Human hemoglobin shares high similarity with bovine, canine, porcine and equine hemoglobin when comparing their amino acid sequences.
[0031] In naturally-occurring hemoglobin inside the red blood cells, the association of an a chain with its corresponding β chain is very strong and does not disassociate under physiological conditions. However, the association of one αβ dimer with another αβ dimer is fairly weak outside red blood cells. The bond has a tendency to split into two αβ dimers each approximately 32 kDa. These undesired dimers are small enough to be filtered by the kidneys and be excreted, with the resuit being potential rénal injury and substantially decreased intravascular rétention time.
[0032] Therefore, it is necessary to stabilize any hemoglobin that is used outside of red blood cells both for efficacy and safety. The process for producing the stabilized hemoglobin is outlined below; an overview of the process of the présent invention is presented in the flow chart of FIG. 1.
[0033] Initially, a whole blood source is selected as a source of hemoglobin from red blood cells. Mammalian whole blood is selected including, but not limited to, human, bovine, porcine, equine, and canine whole blood. The red blood cells are separated from the plasma, filtered, and washed to remove plasma protein impurities.
[0034] In order to release the hemoglobin from the red blood cells, the cell membrane is lysed. Although various techniques can be used to lyse red blood cells, the présent invention uses lysis under hypotonie conditions in a manner which can be precisely controlled at volumes suitable for industriai-scale production. To this end, an instant cytolysis apparatus as seen in FIG. 2 is used to lyse the red blood cells. Hypotonie lysis créâtes a solution of lysate including hemoglobin and a waste retentate. To enable industrial-scale production, the lysis is carefully controlled such that only red blood cells are lysed without lysing white blood cells or other cells. In one embodiment, the size of the instant cytolysis apparatus is selected such that the red blood cells traverse the apparatus in 2 to 30 seconds or otherwise a time sufficient to lyse the red blood cells and preferably, 30 seconds. The instant cytolysis apparatus includes a static mixer. Deionized and distilled water is used as a hypotonie solution. Of course it is understood that the use of other hypotonie solutions having different saline concentrations would resuit in different time periods for red blood cell lysis. Because the controlled lysis procedure lyses the red blood cells only, not white blood cells or cellular matter, it minimizes the release of toxic proteins, phospholipids or DNA from white blood cells and other cellular matter. A hypertonie solution is added immediately after 30 seconds, that is, after the red blood-cell containing solution has traversed the static mixer portion of the instant cytolysis apparatus. The résultant hemoglobin has a higher purity and lower levels of contaminants such as undesired DNA and phospholipids than hemoglobin resulted from using other lysis techniques. Undesired nucleic acids from white blood cells and phospholipids impurities are not detected in the hemoglobin solution by polymerase chain reaction (détection limit = 64 pg) and high performance liquid chromatography (HPLC, détection limit = l pg^ml) method respect ively.
[0035] At this stage in the process, the hemoglobin solution is purified to remove various protein and other impurities. This purification can be ultrafiltration based, chromatography based, or a combination of one or more ultrafiltration and/or chromatography processes. In an exemplary embodiment, two ultrafiltration processes are performed: one which removes impurities having molecular weights greater than hemoglobin before flowthrough column chromatography, and another which removes impurities having molecular weights less than hemoglobin after flowthrough column chromatography. The latter ultrafiltration process concentrâtes the hemoglobin. In some embodiments, a 100 kDa filter is used for the first ultrafiltration, while a 30 kDa filter is used for the second ultrafiltration.
[0036] Flowthrough column chromatography is used to remove protein impurities in the purified hemoglobin solution such as immunoglobin-G, albumin and carbonic anhydrase. In some embodiments, column chromatography is carried out by using one or a combination of commercially available ion exchange columns such as a DEAE column, CM column, hydroxyapatite column, etc. The pH for column chromatography is typically from 6 to 8.5. In one embodiment, a flowthrough CM column chromatography step is used to remove protein impurities at pH 8.0. Enzyme-linked immunosorbent assay (ELISA) and HPLC method are performed to detect the protein impurities and phospholipids remaining in the sample after elutîon from the column chromatography. This unique flowthrough column chromatography séparation enables a continuous séparation scheme for industrial-scale production. The ELISA resuit shows that the amount of these impurities is substantially low in the eluted hemoglobin (immunoglobin-G: 44.3 ng/ml; albumin; 20.37 ng/ml; carbonic anhydrase: 81.2 pg/ml). The protein impurities removal results using different kinds of columns with different pH values are shown in Table l below.
Table l
Removal percentage (%)
| Column (pH condition) | Carbonic anhydrase | Albumin | Immunoglobin-G |
| DEAE (at pH 7.5) | — | 68 | 29.8 |
| DEAE (at pH 7.8) | — | 60 | 50.9 |
| CM (at pH 6.2) | — | 32 | 21.8 |
| CM (at pH 8.0) | 5.6 | 53.2 | 66.4 |
| Hydroxyapatite (at pH 7.5) | 4.5 | 23.5 | 22.8 |
[0037] Following the column chromatographie process, the hemoglobin is subjected to cross-linking by DBSF. The conditions are selected such that cross-linking occurs between the beta-beta subunits is favored and the résultant product has greater than 50% beta-beta cross-linking. For cross-linking under deoxygenated condition, the resulting hemoglobin has a low oxygen affinity with a higher p50 value compared with the native hemoglobin of the same species measured under substantially similar conditions. For example, for bovine hemoglobin, the native bovine hemoglobin has a p50 value on the order of 23-29 mm Hg. The crosslinked bovine hemoglobin formed under deoxygenated conditions in the présent invention has a p50 value on the order of 38-50 mm Hg. Lower oxygen affmity means that the tetramer can “offload” oxygen to a target more easily than a material with a higher oxygen affinity. For cross-linking of bovine hemoglobin under oxygenated conditions, a material with a higher oxygen affmity is formed with a lower p50 value, less than approximately 23 mm Hg, compared with native bovine hemoglobin which has a p50 value on the order of 23-29 mm Hg. Lower oxygen affmity compositions are used when rapid oxygénation is desired as in cases of tissue hypoxia resulting from extensive blood loss (e.g., hémorrhagie shock). Higher oxygen affmity compositions are useful for oxygénation adjunct thérapies in cancer treatment where a slower delivery rate of oxygen is désirable.
[0038] For human hemoglobin, cross-linking under deoxygenated condition typically produces a majority of alpha-alpha crosslinked hemoglobin with lower oxygen affmity, that is, an oxygen affmity that is decreased on the order of at least 2-fold from native human hemoglobin. Cross-linking under oxygenated conditions tends to favor production of beta-beta crosslinked hemoglobin with a higher oxygen affmity (that is, a lower p50, less than approximately 23 mm Hg), compared with the native human hemoglobin under the same condition (a p50 value on the order of approximately 23-30 mm Hg).
[0039] For deoxygenated cross-linking condition preferably less than 0.1 ppm dissolved oxygen level, it is maintained with a molar ratio of hemoglobin to DBSF from 1:2.5 to 1:4.0 for a period of time from 3 to 16 hours at ambient température (15-25°C), at a pH of around 8-10, preferably around pH8.6-9.2. The résultant crosslinked hemoglobin is tetrameric hemoglobin having a molecular weight of 60-70 kDa, demonstrating that polymeric hemoglobin is not présent. The yield of the DBSF reaction is high, > 99% and the dimer concentration in the final product is low. Optionally, the présent process does not require sulfhydryl treatment reagents such as iodoacetamide to react with the hemoglobin before cross-linking as used in various prior art processes. For cross-linking under oxygenated conditions, an oxygenated environment (such as air, pO2 is around 149mmHg;
or pure O2, pO2 is nearly 760mmHg) is used while the remaining conditions above are substantially the same.
[0040] For bovine hemoglobin, the beta-beta cross-linking is greater than 50%, and preferably greater than 60% for cross-linking under deoxygenated conditions (less than 0.1 ppm dissolved oxygen level). For bovine hemoglobin crosslinked under oxygenated condition, beta-beta cross-linking is also favored, typically at a level greater that 40% betabeta crosslinking.
[0041 ] For human hemoglobin, cross-linking under oxygenated conditions favors beta-beta cross-linking.
[0042] Following cross-linking, phosphate buffered saline (PBS), a physiological buffer, is exchanged for the cross-linking solution and any residual chemicals are removed by tangentîal flow filtration.
[0043] Following cross-linking, the présent invention provides a heat processing step (High Température Short Time, HTST) for the crosslinked tetrameric hemoglobin solution. The heat treatment takes place in a deoxygenated environment. Prior to heat treatment, Nacetyl cysteine is optionally added to prevent formation of met-hemoglobin (inactive hemoglobin). After the heat processing step, the solution is cooled and N-acetyl cysteine is optionally added to maintain a low level of met-hemoglobin. If N-acetyl cysteine is added before and after heat treatment, the amount added before heat treatment is approximately 0.2%, while the amount added after heat treatment is approximately 0.025% to 0.4%. However, if N-acetyl cysteine is added only after heat treatment, then the amount added is 0.025%-0.4%. In one embodiment, the amount of N-acetyl cysteine added after heat treatment is 0.2%-0.4%. In another embodiment, the amount of N-acetyl cysteine added after heat treatment is 0.025%-0.2%.
[0044] In some embodiments, the crosslinked tetrameric hemoglobin solution is heated in a deoxygenated environment (less than 0.I ppm dissolved oxygen level) under a range of — températures from 50°C to 95°C for durations from 0.5 minutes to 10 hours. In some embodiments, the crosslinked tetrameric hemoglobin solution is heated under a range of températures from 70°C to 95°C and for durations from 30 seconds to 3 hours. In some preferred embodiments, the crosslinked tetrameric hemoglobin solution is heated under 80°C for 30 minutes. And yet in other preferred embodiments, the crosslinked hemoglobin solution is heated to 90°C for 30 seconds to 3 minutes, then rapidly cooled down to approximately 25°C in approximately 15 to 30 seconds, and the N-acetyl cysteine is optionally added as set forth above.
[0045] To analyze the outcome of the HTST heat processing step, a HPLC analytical method is used to detect the amount of dimer after this heat processing step. The mobile phase for HPLC analysis contains magnésium chloride (0.75M) which can separate dimer (non-stabilized tetramer) and heat stable crosslinked tetrameric hemoglobin. For promoting hemoglobin dissociation into dimers, magnésium chloride is approximately 30 times more effective than sodium chloride at the same ionic strength. The heat processing step also acts as a dénaturation step to dramatically remove unwanted protein impurities in the crosslinked tetrameric hemoglobin (undetectable in immunoglobin-G; 96.15% decrease in albumin; 99.99% decrease in carbonic anhydrase). Enzyme-linked immunosorbent assay (ELISA) is performed to detect the protein impurities in the sample. Thus the purified, heat stable crosslinked tetrameric hemoglobin solution has an undetectable level of dimer (below détection limit: 0.043%), and immunoglobin-G, and a very low amount of albumin (0.02 pg/ml) and carbonic anhydrase (0.014 gg/ml). FIG. 3 shows that the dimeric form of hemoglobin is undetectable in a HPLC System. Table 2 shows the experimental results regarding the protein impurities and dimer removal by the HTST heat processing step. This HTST heat processing step enables the sélective séparation of heat stable crosslinked tetramer from unstable tetramer (e.g., non crosslinked tetramer) and dimer.
[0046] Table 2
| Immunoglobin-G (gg/ml) | Albumin (pg/ml) | Carbonic anhydrase (pg/ml) | Tetramer (%) | Dimer (%) | |
| No heat | 0.36 | 0.57 | 355.41 | 90.1 | 5.4 |
| treatment | |||||
| 80°C for 10min | Not détectable | 0.33 | 0.032 | 92.7 | 3.4 |
| 80°C for I5min | Not détectable | 0.14 | 0.022 | 93.3 | 2.9 |
| 80°C for 30min | Not détectable | 0.03 | 0.014 | 96.6 | Not détectable |
| No heat | 0.29 | 0.52 | 261.80 | 91.8 | 5.3 |
| treatment | |||||
| 90°C for 1.0min | Not détectable | 0.21 | >0.063 | 93.4 | 2.0 |
| 90°C for 1.5min | Not détectable | 0.04 | 0.022 | 94.9 | 0.6 |
| 90°C for 2.0min | Not détectable | 0.02 | 0.016 | 96.1 | Not détectable |
[0047] Foilowing the heat processing step for the crosslinked hemoglobin under a deoxygenated condition, the heat stable crosslinked tetrameric hemoglobin is ready for 5 pharmaceutical formulation and packaging. The présent invention describes an air-tight packaging step of the heat stable crosslinked tetrameric hemoglobin solution in a deoxygenated environment. Heat stable crosslinked tetrameric hemoglobin in the présent invention is stable when maintained in a deoxygenated condition for more than two years.
[0048] In this invention, the oxygen carrier-containing pharmaceutical composition is 10 primarily intended for intravenous injection application. Traditionally, prior products use conventional PVC blood bag or Stericon blood bag which has high oxygen permeability which wîll eventually shorten the life span of the product since it tums into inactive methemoglobin rapidly (within a few days) under oxygenated conditions.
[0049] The packaging used in the présent invention results in the heat stable crosslinked tetrameric hemoglobin being stable for more than two years. A multi-layer package of EVA/EVOH material is used to minimize the gas permeability and to avoid the formation of inactive met-hemoglobin. A 100 ml infusion bag designed for use with the purified and heat stable crosslinked tetrameric hemoglobin of the présent invention is made from a five layers EVA/EVOH laminated material with a thickness of 0.4 mm that has an oxygen permeability of 0.006-0.132 cm3 per 100 square inches per 24 hours per atmosphère at room température. This material is a Class VI plastic (as defined in USP<88>), which meets the in-vivo Biological Reactivity Tests and the Physico-Chemical Test and is suitable for fabricating an infusion bag for intravenous injection purpose. This primary bag is particularly useful to protect the heat stable crosslinked tetrameric hemoglobin solution from long tenu oxygen exposure that causes its instability and eventually affects its therapeutic properties.
[0050] For secondary protection of blood products, it has been known to use aluminum overwrap to protect against potentîal air leakage and to maintain the product in a deoxygenated state. However, there is a potentîal of pin holes in the aluminum overwrap that compromises its air tightness and makes the product unstable. Therefore the présent invention uses as secondary packaging an aluminum overwrap pouch which prevents oxygénation and also prevents light exposure. The composition of the overwrap pouch includes 0.012mm of polyethylene terephthalate (PET), 0.007mm of aluminum (Al), 0.015mm of nylon (NY) and 0.1mm of polyethylene (PE). The overwrap film has a thickness of 0.14mm and an oxygen transmission rate of 0.006 cm3 per 100 square inches per 24 hours per atmosphère at room température. This secondary packaging lengthens the stability time for the hemoglobin, extending the product shelf-life.
[0051] The process in this invention is applicable to large scale industrial production of the heat stable crosslinked tetrameric hemoglobin. In addition, the heat stable crosslinked tetrameric hemoglobin in combination with a pharmaceutical carrier (e.g. water, physiological buffer, in capsule form) is suitable for mammalian use.
[0052] The oxygen carrier-containing pharmaceutical composition of the présent invention is useful in improving tissue oxygénation, in cancer treatment, in the treatment of oxygendeprivation disorders such as hémorrhagie shock, and in heart préservation under a low Λ/ι/ζ^ oxygen content environment (e.g. heart transplant). In exemplary embodiments, the dosage is selected to hâve a concentration range of approximately 0.2-1.3 g/kg with an infusion rate of less than 10 ml/hour/kg body weight.
[0053] For the use in the treatment of oxygen-deprivation disorders and for heart préservation, the oxygen carrier-contaîning pharmaceutical composition with a lower oxygen affïnity of the présent invention serves as a blood substitute providing oxygen to a target organ. Lower oxygen affïnity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygénation (e.g. hémorrhagie shock and ex vivo organ préservation). [0054] For applications in cancer treatment, the oxygen carrier-containing pharmaceutical composition with a higher oxygen affïnity of the présent invention serves as a tissue oxygénation agent to improve the oxygénation in tumor tissues, thereby enhancing chemoand radiation sensitivity. A higher oxygen affïnity hemoglobin is useful for applications requiring a slower rate of oxygénation (e.g. cancer adjunct therapy).
Examplcs [0055] The following examples are provided by way of describing spécifie embodiments of this invention without intending to limit the scope of this invention in any way.
[0056] Example 1 [0057] Process Overview [0058] A schematic flow diagram of the process of the présent invention is illustrated in FIG. 1. Bovine whole blood is collected into an enclosed stérile container/bag containing 3.8% (w/v) tri-sodium citrate solution as anti-coagulant. Blood is then immedîately mixed well with tri-sodium citrate solution to inhibit blood clotting. Red blood cells (RBC) are isolated and collected from plasma and other smaller blood cells by an apheresis mechanism. A “cell washer” is used for this procedure with gamma sterilized disposable centrifuge bowl. RBC are washed with an equal volume of 0.9% (w/v sodium chloride) saline.
[0059] Washed RBC are lysed to release hemoglobin content by manipulating hypotonie shock to the RBC cell membrane. A specialized instant cytolysis apparatus for RBC lysis device depicted in FIG. 2 is used for this purpose. Following RBC lysis, hemoglobin molécules are isolated from other proteins by tangential-flow ultrafiltration using a 100 kDa membrane. Hemoglobin in the filtrate is collected for flowthrough column chromatography and further concentrated to 12-14 g/dL by a 30 kDa membrane. Column chromatography is carrîed out to remove the protein impurities.
[0060] The concentrated hemoglobin solution is first reacted with DBSF to form heat stable crosslinked tetrameric hemoglobin molécules. A heat processing step is then performed under deoxygenated conditions at 90°C for 30 seconds to three minutes before final formulation and packaging.
[0061] Example 2 [0062] Time & Controlled Hypotonie lysis and filtration [0063] Bovine whole blood is freshly collected and transported under a cool condition (2 to 10°C). The red blood cells are separated from the plasma via a cell washer and subsequently with a 0.65 pm filtration. After washing the red blood cells (RBC) filtrate with 0.9% saline, the filtrate is disrupted by hypotonie lysis. The hypotonie lysis is performed by using the instant cytolysis apparatus depicted in FIG. 2. The instant cytolysis apparatus includes a static mixer to assist in cell lysis. A RBC suspension with controlled hemoglobin concentration (12-14g/dL) is mixed with 4 volumes of purified water to generate a hypotonie shock to RBC cell membranes. The period of hypotonie shock is controlled to avoid unwanted lysis of white blood cells and platelets. The hypotonie solution passes through the static mixer portion of the instant cytolysis apparatus for 2 to 30 seconds or otherwise a time sufficient to lyse the red blood cells and preferably, 30 seconds. The shock is terminated after 30 seconds by mixing the lysate with 1/10 volume of hypertonie buffer as it exits the static mixer. The hypertonie solution used is 0.1M phosphate buffer, 7.4% NaCl, pH 7.4. The instant cytolysis apparatus of FIG. 2 can process at 50 to 1000 liters of lysate per hour and, preferably at least 300 liters per hour in a continuous manner.
[0064] Following the RBC lysis, the lysate of red blood cells is filtered by a 0.22 pm filter to obtain a hemoglobin solution. Nucleic acids from white blood cells and phospholipids impurities are not detected in the hemoglobin solution by polymerase chain reaction (détection limit = 64 pg) and HPLC (détection limit = 1 pg/ml) method respectively. A first 100 kDa ultrafiltration is performed to remove impurities having a higher molecular weight than hemoglobin. A flowthrough column chromatography is followed to further purify the hemoglobin solution. A second 30 kDa ultrafiltration is then performed to remove impurities having a lower molecular weight than hemoglobin and for concentration. [0065] Example 3 [0066] Viral clearance study on stroma-free hemoglobin solution [0067] In order to demonstrate the safety of the product from this invention, the virus removal abilities of (l) 0.65 μιη diafïltratîon step and (2) 100 kDa ultrafiltration step are demonstrated by virus validation study. This is done by the deliberate spiking of a downscaled version of these two processes with different model viruses (encephalomyocarditis virus, pseudorabies virus, bovine viral diarrhea virus and bovine parvovirus). In this study, four types of viruses (see Table 3) are used. These viruses vary in their biophysical and structural features and they display a variation in résistance to physicaï and chemical agents or treatments.
[0068] Table 3
| Targct Virus | Model Virus | Taxonomy | Genonie | Structure | Size |nm[ | Stability* |
| Hepatitis C virus | Bovine viral diarrhea virus (BVDV) | Flaviviridae | ssRNA | enveloped | 40- 60 | low |
| - | Encephalomyocarditis virus (EMCV) | Picomavirus | ssRNA | non- enveloped | 25- 30 | medium |
| Parvovirus B19 | Bovine parvovirus (BPV) | Parvoviridae | ssDNA | nonenveloped | 18- 26 | very high |
| Hepatitis B virus | Pseudorabies virus (PRV) | Herpesviridae | dsDNA | enveloped | 120- 200 | Low to medium |
The validation scheme is briefly shown in the following Table 4.
[0069] Table 4
| Diafiltration | Ultrafiltration |
| Cel! Washing I | Virus spiking I |
| Virus spiking I | I Ultrafiltration |
| 4 Diafiltration l | I Virus tests |
| Virus tests |
[0070] The summary of the log réduction results of the 4 vîruses in (l) 0.65 pm diafiltration and (2) 100 kDa ultrafiltration is shown in the following Table 5. Ail four 10 viruses, BVDV, BPV, EMCV and PRV, are effectively removed by 0.65 μπτ diafiltration and 100 kDa ultrafiltration.
[0071] Table5
| Viruses | BVDV | BPV | EMCV | PRV | ||||
| Run | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 |
| 0.65pm Diafiltration | 2.69 | 3.20 | 3.73 | 3.53 | 3.25 | >3.90 | 2.67 | 2.63 |
| lOOkDa Ultrafiltration | >4.68 | >4.38 | 5.87 | 5.92 | 3.60 | 3.43 | >6.05 | 3.27 |
| Cumulative maximum | >7.88 | 9.65 | >7.50 | >8.72 | ||||
| Cumulative minimum | >7.07 | 9.40 | 6.68 | 5.90 |
Annotation:
> no residual infectivity determined yx/ [0072] Example 4 [0073] Flowthrough column chromatography [0074] A CM column (commercially available from GE healthcare) is used to further remove any protein impurities. The starting buffer is 20mM sodium acetate (pH 8.0), and the elution buffer is 20mM sodium acetate, 2M NaCl (pH 8.0), After the équilibration of the CM column with starting buffer, the protein sample is loaded into the column. The unbound protein impurities are washed with at least 5 column volume of starting buffer. The elution is performed using 25% elution buffer (0-0.5M NaCl) in 8 column volume. The elution profile is shown in FIG. 4; the hemoglobin solution is in the flowthrough fraction. The purity of the flowthrough fraction is analyzed by ELISA. The results are indicated în the following Table 6.
[0075] Table 6
| Protein impurities | |||
| Immunoglobin-G | Carbonic anhydrase | Albumin | |
| Before CM column | 1320 ng/ml | 860.3 pg/ml | 435.2 ng/ml |
| Flowthrough (containing hemoglobin) | 44.3 ng/ml | 81.2 pg/ml | 20.4 ng/ml |
[0076] As the hemoglobin solution is in the flowthrough from the CM column chromatography at pH 8 (not in the eluate), it is a good approach for continuous industrial scale operation. The first ultrafiltration set-up is connected directly to the flowthrough CM column chromatography System, and the flowthrough tubing can be connected to the second ultrafiltration set-up for industrial scale operation. The schematic industrial process configuration is shown in FIG. 5.
[0077] Example 5 [0078] Préparation of heat stable crosslinked tetrameric hemoglobin [0079] (5a) Cross-linking reaction with DBSF under a deoxygenated condition [0080] The cross-linking reaction is carried out in a deoxygenated condition, that is, less than 0.1 ppm dissolved oxygen level. DBSF is added to the hemoglobin solution to form crosslinked tetrameric hemoglobin without formation of polymeric hemoglobin. DBSF stabilization procedure stabilizes the tetrameric form of hemoglobin (65 kDa) and prevents dissociation into dimers (32 kDa) which are excreted through the kidneys. In this embodiment, a molar ratio of hemoglobin to DBSF of 1:2.5 is used and the pH is 8.6. This process is carried out for a period of 3-16 hours at ambient température (15-25°C) in an inert atmosphère of nitrogen to prevent oxidation of the hemoglobin to form ferrie methemoglobin which is physiologicaliy inactive (dissolved oxygen level maintained at less than O.l ppm). The completeness of DBSF reaction is monitored by measuring the residual DBSF using HPLC. The yield of the DBSF reaction is high, > 99%. The production of beta-beta crosslinks is on the order of at least about 40%.
[0081] (5b) HTST heat processing step [0082] A High Température Short Time (HTST) processing apparatus is shown in FIG 6. A heat processing step using the HTST processing apparatus is performed on the crosslinked tetrameric hemoglobin. In this example, the condition for heat treatment is 90°C for 30 seconds to 3 minutes, and preferably 45 to 60 seconds although other conditions can be selected as discussed above and the apparatus modified accordingly. A solution containing crosslinked hemoglobin optionally with 0.2% of N-acetyl cysteîne added thereto is pumped into a HTST processing apparatus (first section of the HTST heat exchanger is pre-heated and maintained at 90°C) at a flow rate of 1.0 liter per minute, the résidence time of the first section of the apparatus is between 45 to 60 seconds, then the solution îs passed through at the same flow rate into another section of the heat exchanger that is maintained at 25°C. The time required for cooling is between 15 to 30 seconds. After cooling down to 25°C, N-acetyl cysteine is ïmmediately added at a concentration of 0.2% to 0.4%. The set-up of the heat processing apparatus is easily controlled for industrial operation. A température profile with dimer content is shown in FIG. 7. If the hemoglobin îs not crosslinked, it is not heat stable and forms a precipitate after the heat processing step. The precipitate is then removed by a centrifugation or a filtration to form a clear solution thereafter. sjL· [0083] The following Table 7 shows that protein impurities such as immunoglobîn-G, albumin, carbonic anhydrase and undesirable non-stabilized tetramer or dimers are removed after the heat processing step. The amount of immunoglobin-G, albumin and carbonic anhydrase are measured using an ELISA method, while the amount of dimer is determined by an HPLC method. The purity of heat stable crosslinked tetrameric hemoglobin is extremely high after the HTST heat processing step, in the range of 98.0 to 100%.
[0084] Table 7
| Sample condition | Protein impurities (by ELISA) | By HPLC | |||
| Immunoglobin-G (pg/ml) | Albumin (pg/ml) | Carbonic anhydrase (pg/ml) | Tetramer (%) | Dimer (%) | |
| No heat treatment | 0.29 | 0.52 | 261.80 | 91.8 | 5.3 |
| 90°C for 2min | Not détectable | 0.02 | 0.016 | 96.1 | Not détectable |
| Removal (%) | 100.0 | 96.15 | 99.99 | — | 100.0 |
[0085] (5c) Prévention of Met-hemoglobin formation by 0.025-0.2% NAC Addition [0086] Following the heat treatment and cooling, N-acetyl Cysteine (NAC) is immediately added into the crosslinked tetrameric hemoglobin at a concentration of approximately 0.025-0.2% to prevent the formation of met-hemoglobin. At different time interval, the percentage of met-hemoglobin is measured by Co-oximetry method. Table 8 shows the percentage of met-hemoglobin in the crosslinked tetrameric hemoglobin after NAC addition over 5 months. As shown in Table 8, the met-hemoglobin level in the heat-treated crosslinked tetrameric hemoglobin is kept steady and very low after NAC addition, in a range of 1.8-5.1%. vY [0087] Table 8
| Total NAC level | Met-hemoglobin% in Heat-treated Crosslinked Tetrameric Hemoglobin After Adding NAC | |||
| 1 week | l month | 3 month s | 5 months | |
| 0.2% NAC | 3.8 | 2.5 | 3.5 | 4.3 |
| 0.1% NAC | 5.1 | 4.3 | 2.9 | 3.8 |
| 0.05% NAC | 3.7 | 3.3 | 2.3 | 4.0 |
| 0.025% NAC | 3.6 | 2.5 | 1.8 | 2.7 |
[0088] Example 6 [0089] Packaging [0090] Because the product of the présent invention is stable under deoxygenated conditions, the packaging for the product is important to minimize gas permeability. For intravenous application, a custom designed, 100 ml infusion bag is made from a five-layer EVA/EVOH laminated material with a thickness of 0.4 mm that has an oxygen permeability of 0.006 to 0.132 cm3 per 100 square inches per 24 hours per atmosphère at room température. This spécifie material is a Class VI plastic (as defined in USP<88>), which meets the in-vivo biological reactivity tests and the physico-chemical tests and are suitable for fabricating containers for intravenous injection purpose (note that other forms of packaging can be made from this material as well depending upon the desired application). A secondary packaging aluminum overwrap pouch is also applied to the primary packaging infusion bag that provides an additional barrier, mimmizing light exposure and oxygen diffusion. The layers of the pouch comprise: 0.012mm of Polyethylene terephthalate (PET), 0.007mm of Aluminum (Al), 0.015mm of Nylon (NY) and 0.1mm of Polyethylene (PE). The overwrap film has a thickness of 0.14mm and oxygen transmission rate of 0,006 cm3 per 100 square inches per 24 hours per atmosphère at room température. A schematic depiction of the infusion bag is depicted in FIG. 8. The overall oxygen permeability for each infusion bag according to the présent invention is 0.0025 cm3 per 24 hours per atmosphère at room température.
[0091] Example 7 [0092] Characterization of crosslinked bovine Hb (Deoxygenated cross-linking condition) [0093] (7a) Séparation of globin chains by Reverse Phase High Performance Liquid Chromatography (HPLC) [0094] The globin chains of native bovine hemoglobin and crosslinked globin chains of DBSF crosslinked bovine hemoglobin are resolved on a VYDAC C4 column using the gradients developed by Shelton et al., 1984 with minor modification.
[0095] (7b) Sodium dodecyl sulfate polyacrylamide gel electrophoresîs (SDS-PAGE) analysis of DBSF crosslinked bovine hemoglobin [0096] Native bovine hemoglobin and DBSF crosslinked bovine hemoglobin solution are prepared by mixing with reducing sample buffer (62 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 5% (v/v) mercaptoethanol and 2.3% (w/v) SDS), and heated at 95°C for 10 min. The sample mixture is resolved using a 15% acrylamide slab gel with a 4% stacking gel. The electrophoresîs is run with a constant current of 60 mA. After electrophoresîs, the SDS-PAGE gel is stained with 0.1% (w/v) Coomassie Blue R350, 20% (v/v) methanol and 10% (v/v) acetic acid. To estimate the percentage of different types of cross-linking in DBSF crosslinked bovine hemoglobin, the intensities of the resolved protein bands expressed in Black Light Unit (BLU) are quantified using Lumi-Analyst 3.1 Software.
[0097] (7c) Trypsin digestion of reduced globin chain [0098] The protein band corresponding to the major crosslinked globin chain is excised from the SDS-PAGE gel, eut into cubes (l X l mm), and de-stained with 10% methanol/10% acetic acid. The de-stained gel cubes are reduced with 10 mM DTT in 25 mM NH4CO3 and alkylated with 55 mM idoacetamide in 25 mM NH4CO3 for 45 min in dark, and then in-gel digested with 20 ng/μΙ modified trypsin in 25 mM NH4CO3 at 37°C overnight. After trypsin digestion, the trypsin-digested peptides are extracted by diffusion into 50% (v/v) acetonitrile (ACN) and l% (v/v) trifluoroacetic acid (TFA), [0099] (7d) Matrix Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry (MS) analysis [00100] The trypsin digested peptides extracted from the protein band are spotted onto an Anchorchip plate, which is pre-spotted with l μΐ of matrix solution (2 mg/ml cyano-4 hydroxycinnamic acid, saturated in 50% ACN/ 0.1% TFA, and allowed to air-dry. After drying, the sample spot is washed with 10 mM monophosphate buffer and recrystallized using a solution of éthanol: acetone: 0.1% TFA (6:3:1 ratio). MALDI-TOF MS analysis is performed with a Bruker Autoflex III (Bruker Daltonic GmbH, Bremen, Germany) operated in the reflectron mode over the m/z range of 800-3500 Da and the parameters are set as follows: ion source 25 kV for peptide mass fingerprint (PMF), and reflector 26.3 kV for PMF. External calibration is performed using a Bruker Peptide Mix Calibration Standard. The peaks with a S/N ratio over 4 are automatically labeled by Flex-Analysis (Bruker Daltonic GmbH, Bremen, Germany). The MS data is further analyzed through MASCOT 2.2.04 and Biotools 2.1 software (Bruker Daltonic GmbH, Bremen, Germany), and these data were searched against Mammalian proteins in NCBI nonreduntant (NCBInr) database. The following parameters are used for database searches: monoisotopic mass accuracy <250 ppm, parent charge +1, missed cleavages 1, carbamidomethylation of cysteine as fixed modification, oxidation of méthionine as variable modification.
[00101] (7e) Liquid chromatography - electrospray ionization (LC-ESI) tandem mass spectrometry (MS/MS) analysis [00102] Nano-LC MS/MS analysis of the trypsîn digested peptides from the protein band is performed using a capillary HPLC coupled directly to HCT Ultra ESI- ion trap mass spectrometer (Bruker Daltonic GmbH, Bremen, Germany). Peptide digests are dissolved in 0.1% formic acid/2% ACN prior to column injection. A gradient from 4-90% (0.001% formic acid and 0.001% formic acid in 80% ACN) is used for peptide séparation using a Cl8 column (15 cm X 75 nm, LC PACKINGS). The flow rate is 250 ng/min at 25°C. Eluates from a Cl8 column are entered into the HCT Ultra ESI- ion trap mass spectrometer, operated in linear mode for online analysis. The ion trap mass spectrometer is optimized with the nanosource with a spray voltage of 137V and a heated capillary température of 160°C. The accumulation time for peptide ions in the ion trap is set to be 200 ms, and the mass to charge ratio selected for MS/MS analysis is from 100 to 1800 Da with a charge state 1-3.
[00103] The reverse phase HPLC on a VYDAC C4 column, monitored at a wavelength of 220nm, is employed to separate different types of cross-linking occurring between a and β chains in the DBSF crosslinked bovine hemoglobin. The chromatographie patterns obtained using bovine hemoglobin before and after cross-linking with DBSF are shown in
FIG. 9. In FIG. 9, the a chains are more mobile than the β chains of native bovine hemoglobin (as shown with dashed line). Their identities are confirmed by MALDI-TOF analysis. After the reaction with DBSF, the β chains are crosslinked while a large majority of a chains are left alone (as shown with solid line). As a conséquence of cross-linking with DBSF, 6 major globin peaks with greater hydrophobicity than the native β chains are 10 formed. The crosslinked globin chains in the DBSF crosslinked bovine hemoglobin are also resolved by 15% SDS-PAGE, as shown in FIG. 10. The major crosslinked globin chain (B6 in FIG. 10) is subjected to trypsin digestion and subséquent MALDI-TOF analysis, and it is identified as beta globin chain only, based on its peptide mass fingerprint, as shown in FIG. 11.
[00104] While the foregoing invention has been described with respect to various embodiments, such embodiments are not limiting. Numerous variations and modifications would be understood by those of ordinary skill in the art. Such variations and modifications are considered to be included within the scope of the following daims.
9 FEV 2014
EKEMEJXSAGHT Sari jZb.p. p32iw2 YAÇ&NDE - giMBKOUN TéL- FakG722 31 fe7 53
Claims (27)
- l. A method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition, the oxygen carrier-containing pharmaceutical composition including hemoglobin, the hemoglobin consisting essentially of nonpolymeric crosslinked tetrameric hemoglobin having a beta-beta cross-linking of greater than 40%, the method comprising:a) providing mammalian whole blood including at least red blood cells and plasma;b) separating the red blood cells from the plasma in the mammalian whole blood;c) filtering the red blood cells that were separated from the plasma to obtain a filtered red blood cell fraction;d) washing the filtered red blood cell fraction to remove plasma protein impurities, resulting in washed red blood cells;e) disrupting the washed red blood cells to create a solution comprising a lysate of disrupted red blood cells;f) performing filtration to remove at least a portion of the waste retentate from the lysate;g) extracting a first hemoglobin solution from the lysate;h) performing at least one purification process to remove one or more of viruses, waste retentate, or protein impurities;i) cross-linking the first hemoglobin solution by bis-3,5-dibromosalicyl fumarate to form crosslinked hemoglobin in an oxygenated environment wherein the crosslinked hemoglobin is non-polymeric crosslinked tetrameric hemoglobin having at least 40% betabeta cross-linking;j) removing any residuai chemicals;k) heat treating the crosslinked hemoglobin in a deoxygenated environment to dénaturé and precipitate any residuai non-stabilized/ non-crosslinked hemoglobin, any dimeric hemoglobin and any other protein impurities such that the resulting heat stable crosslinked tetrameric hemoglobin has an undetectable concentration of dimer and consists essentially of non-polymeric crosslinked tetrameric hemoglobin with a beta-beta cross-linking of at least 40% and an oxygen affinity greater than the oxygen affinity of native hemoglobin of the same species measured under substantially similar conditions;l) removing precipitate by a centrifugation or a filtration to form a clear solution; andm) adding the purified and heat stable crosslinked tetrameric hemoglobin to a pharmaceutically acceptable carrier.
- 2. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim l wherein the heat processing step is a high température short time (HTST) process conducted at approximately 70°C to 95°C for 30 seconds to 3 hours followed immediately by cooling and adding N-acetyl cysteine in an amount of 0.2 to 0.4% immediately following the cooling.
- 3. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim l wherein the whole blood is bovine whole blood and the beta-beta cross-linking is greater than 50% and the p50 value is less than approximately 23 mm Hg.
- 4. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim l wherein the whole blood is bovine whole blood and the beta-beta cross-linking is greater than 60% and the p50 value is less than approximately 23 mm Hg.
- 5. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim l wherein the purification is performed using chromatography, the chromatography including use of one or more cation-exchange columns or anîon-exchange columns.
- 6. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim 5 wherein the chromatography column is one or more DEAE, CM and/or hydroxyapatite columns.
- 7. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim l wherein the whole blood is human blood.
- 8. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim 1 wherein the whole blood is porcine blood, equine blood, or canine blood.
- 9. A method for the préparation of a highly purified and heat stable oxygen carrier containing pharmaceutical composition according to claim 1 further comprising packaging the hemoglobin solution in a low oxygen permeability package such that hemoglobin solution has a shelf life on the order of two years.
- 10. A highly purified and heat stable oxygen carrier-containîng pharmaceutical composition comprising hemoglobin, wherein the hemoglobin consisting essentîally of non-polymeric crosslinked tetrameric hemoglobin having beta-beta cross-linking of greater than 40% formed by the process of claim 1.
- 11. A highly purified and heat stable oxygen carrier-containing pharmaceutical composition comprising hemoglobin, wherein the hemoglobin consisting essentîally of non-polymeric crosslinked tetrameric hemoglobin having beta-beta cross-linking of greater than 60% formed by the process of claim 4.
- 12. The composition of claim 10 for oxygenating tissue, wherein said composition is administered either in vivo or ex vivo.
- 13. The composition of claim 11 for oxygenating tissue, wherein said composition is administered either in vivo or ex vivo.
- 14. A method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition, the oxygen carrier-containing pharmaceutical composition including hemoglobin, the hemoglobin consisting essentially of nonpolymeric crosslinked tetrameric hemoglobin having a beta-beta cross-linking of greater than 50%, the method comprisîng:a) providing mammalian whole blood including at least red blood cells and plasma;b) separating the red blood cells from the plasma in the mammalian whole blood;c) filtering the red blood cells that were separated from the plasma to obtain a filtered red blood cell fraction;d) washing the filtered red blood cell fraction to remove plasma protein impurities, resulting in washed red blood cells;e) disrupting the washed red blood cells to create a solution comprisîng a lysate of disrupted red blood cells;f) performing filtration to remove at least a portion of the waste retentate from the lysate;g) extracting a first hemoglobin solution from the lysate;h) performing at least one purification process to remove one or more of viruses, waste retentate, or protein impurities;i) cross-linking the first hemoglobin solution by bis-3,5-dibromosalicyl fumarate to form crosslinked hemoglobin in a deoxygenated environment wherein the crosslinked hemoglobin is non-polymeric crosslinked tetrameric hemoglobin having at least 50% betabeta cross-linking;j) removing any residual chemicals;k) heat treating the crosslinked hemoglobin in a deoxygenated environment to dénaturé and precipitate any residual non-stabilized/ non-crosslinked hemoglobin, any dimeric hemoglobin and any other protein impurities such that the resulting heat stable crosslinked tetrameric hemoglobin has an undetectable concentration of dimer and consists essentially of non-polymeric crosslinked tetrameric hemoglobin with a beta-beta cross-linking of at least 50% having an oxygen affinity less than the oxygen affinity of native hemoglobin of the same species measured under substantially similar conditions;l) removing precipitate by a centrifugation or a filtration to form a clear solution; andm) adding the purified and heat stable crosslinked tetrameric hemoglobin to a pharmaceutically acceptable carrier. vJ~
- 15. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim 14 wherein the whole blood is bovine whole blood and the oxygen affinity of the crosslinked tetrameric bovine hemoglobin has a p50 value on the order of approximately 38 to 50 mm Hg.
- 16. A method for the préparation of a highly purified and heat stable oxygen carrier containing pharmaceutical composition according to claim 14 further comprising packaging the hemoglobin solution in a low oxygen permeability package such that hemoglobin solution has a shelf life on the order of two years.
- 17. A highly purified and heat stable oxygen carrier-containing pharmaceutical composition comprising hemoglobin, wherein the hemoglobin consisting essentially of non-polymeric crosslinked tetrameric hemoglobin having beta-beta cross-linking of greater than 50% formed by the process of claim 14.
- 18. A highly purified and heat stable oxygen carrier-containing pharmaceutical composition comprising hemoglobin, wherein the hemoglobin consisting essentially of non-polymeric crosslinked tetrameric hemoglobin having beta-beta cross-linking of greater than 60% formed by the process of claim 15.
- 19. The composition of 17 for oxygenating tissue, wherein said composition is administered either in vivo or ex vivo.
- 20. The composition of 18 for oxygenating tissue, wherein said composition is administered either in vivo or ex vivo.
- 21. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim 1 wherein the heat processing step is a high température short time (HTST) process conducted at approximately 70°C to 95°C for 30 seconds to 3 hours followed immediately by cooling and adding N-acetyl cysteine in an amount of 0.025% to 0.4% immediately following the cooling. —
- 22. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim l wherein the heat processing step is a high température short time (HTST) process conducted at approximately 70°C to 95°C for 30 seconds to 3 hours followed immediately by cooling and adding N-acetyl cysteine in an amount of 0,025% to 0.2% immediately following the cooling.
- 23. A method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition, the oxygen carrier-containing pharmaceutical composition including hemoglobin, the hemoglobin consisting essentially of nonpolymeric crosslinked tetrameric hemoglobin having a beta-beta cross-linking of greater than 40%, the method comprising:a) providing mammalian whole blood including at least red blood cells and plasma;b) separating the red blood cells from the plasma in the mammalian whole blood;c) filtering the red blood cells that were separated from the plasma to obtain a filtered red blood cell fraction;d) washing the filtered red blood cell fraction to remove plasma protein impurities, resulting in washed red blood cells;e) disrupting the washed red blood cells to create a solution comprising a lysate of disrupted red blood cells;f) performing filtration to remove at least a portion of the waste retentate from the lysate;g) extracting a first hemoglobin solution from the lysate;h) performing at least one purification process to remove one or more of viruses, waste retentate, or protein impurities;i) cross-linking the first hemoglobin solution by bis-3,5-dibromosalicyl fumarate to form crosslinked hemoglobin in an oxygenated environment wherein the crosslinked hemoglobin is non-polymeric crosslinked tetrameric hemoglobin having at least 40% betabeta cross-linking;j) removing any residual chemicals;k) heat treating the crosslinked hemoglobin in a deoxygenated environment to dénaturé and precipitate any residual non-stabilized/ non-crosslinked hemoglobin, any dimeric hemoglobin and any other protein impurities such that the resulting heat stable crosslinked tetrameric hemoglobin has an undetectable concentration of dimer and consists essentially of non-polymeric crosslinked tetrameric hemoglobin with a beta-beta cross-linking of at least 40% and an oxygen affinity greater than the oxygen affinity of native hemoglobin of the same species measured under substantially simiiar conditions;l) cooling the resulting heat stable crosslinked hemoglobin;m) adding 0.025%-0.4% of N-acetyl cysteine;n) removing precipitate by a centrifugation or a filtration to form a clear solution; ando) adding the purified and heat stable crosslinked tetrameric hemoglobin to a pharmaceutically acceptable carrier.
- 24. The method for the préparation of a highly purified and heat stable oxygen carrîercontaining pharmaceutical composition according to claim 14 wherein the heat processing step is a high température short time (HTST) process conducted at approximately 70°C to 95°C for 30 seconds to 3 hours followed immediately by cooling and adding N-acetyl cysteine in an amount of 0.025% to 0.4% immediately following the cooling.
- 25. The method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition according to claim 14 wherein the heat processing step is a high température short time (HTST) process conducted at approximately 70°C to 95°C for 30 seconds to 3 hours followed immediately by cooling and adding N-acetyl cysteine in an amount of 0.025% to 0.2% immediately following the cooling.
- 26. The method for the préparation of a highly purified and heat stable oxygen carriercontaîning pharmaceutical composition according to claim 14 wherein the heat processing step is a high température short time (HTST) process conducted at approximately 70QC to 95°C for 30 seconds to 3 hours followed immediately by cooling and adding N-acetyl cysteine ΐη an amount of 0.2% to 0.4% immediately following the cooling. —
- 27. A method for the préparation of a highly purified and heat stable oxygen carriercontaining pharmaceutical composition, the oxygen carrier-containing pharmaceutical composition including hemoglobin, the hemoglobin consisting essentially of nonpolymeric crosslinked tetrameric hemoglobin having a beta-beta cross-linking of greater than 50%, the method comprising:a) providing mammalian whole blood including at least red blood cells and plasma;b) separating the red blood cells from the plasma in the mammalian whole blood;c) filtering the red blood cells that were separated from the plasma to obtain a filtered red blood cell fraction;d) washing the filtered red blood cell fraction to remove plasma protein impurities, resulting in washed red blood cells;e) disrupting the washed red blood cells to create a solution comprising a lysate of disrupted red blood cells;f) performing filtration to remove at least a portion of the waste retentate from the lysate;g) extracting a first hemoglobin solution from the lysate;h) performing at least one purification process to remove one or more of viruses, waste retentate, or protein impurities;i) cross-linking the first hemoglobin solution by bis-3,5-dibromosalicyl fumarate to form crosslinked hemoglobin in a deoxygenated environment wherein the crosslinked hemoglobin is non-polymeric crosslinked tetrameric hemoglobin having at least 50% betabeta cross-linking;j) removing any residual chemicals;k) heat treating the crosslinked hemoglobin in a deoxygenated environment to dénaturé and precipitate any residual non-stabilîzed/ non-crosslinked hemoglobin, any dimeric hemoglobin and any other protein impurities such that the resulting heat stable crosslinked tetrameric hemoglobin has an undetectable concentration of dimer and consists essentially of non-polymeric crosslinked tetrameric hemoglobin with a beta-beta cross-linking of at least 50% having an oxygen afïinity less than the oxygen affinity of native hemoglobin of the same species measured under substantially similar conditions;l) cooling the resulting heat stable crosslinked tetrameric hemoglobin;m) adding 0.025%-0.4% N-acetyl cysteine;n) removing precipitate by a centrifugation or a filtration to form a clear solution; ando) adding the purified and heat stable crosslinked tetrameric hemoglobin to a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61/529279 | 2011-08-31 | ||
| US13/225797 | 2011-09-06 | ||
| US13/275366 | 2011-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA16419A true OA16419A (en) | 2015-10-15 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012300475B2 (en) | Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking | |
| AU2011221433B2 (en) | A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof | |
| EP2399606B1 (en) | A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition | |
| US20110319332A1 (en) | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition | |
| AU2012282692B2 (en) | A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications | |
| OA16419A (en) | Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking. | |
| NZ620913B2 (en) | Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking | |
| US20110319858A1 (en) | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical compositions and the use thereof | |
| OA17703A (en) | A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications. | |
| OA16231A (en) | A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition. |